The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.
Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma Staging System
Clinically suspected neuroblastic tumors.
Patients who receive naxitamab as part of their standard of care
None
Patients will be offered participation in this study by their attending oncologist in the Department of Pediatrics at Memorial Sloan Kettering Cancer Center.
Cohort
Prospective
Tumor and Marrow Markers
Other interventionTumor and Marrow Markers
To study the molecular-genetic makeup and metastasis of neuroblastic tumors.
Before surgery a maximum of 5 blood drawings (20-30 ml) will be performed per year (at least one month apart) per patient
To study the correlation of these biologic markers with clinical outcome.
Before surgery and a maximum of 5 blood drawings (20-30 ml) will be performed per year (at least one month apart) per patient
To relate neuroblastic tumor and embryonic neuroectodermal cell circuitry.
Up to six fetal adrenal samples will be obtained (without patient identifiers) from gestational week 20, when neuroblasts are present and thought to be differentiating within the fetal adrenal gland.
Click on the lead sponsor to view all of their trials.
Memorial Sloan Kettering Cancer Center
Lead sponsor
Southern Illinois University
Collaborator
Spanish National Cancer Center
Collaborator
St. Jude Children's Research Hospital
Collaborator
Washington University School of Medicine
Collaborator
University of Texas
Collaborator
Weill Medical College of Cornell University
Collaborator
